NCT00403325View on ClinicalTrials.gov

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

August 31, 2006

Conditions

Central Serous Chorioretinopathy

Interventions

DRUG

rhuFab V2 [ranibizumab] ( Lucentis )

Trial Locations (1)

10022

Vitreous Retina Macula Consultants of New York, P.C., New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Vitreous -Retina- Macula Consultants of New York

OTHER